GU Cancers 2025 | Comparing avemlumab and EV with pembrolizumab in first line bladder cancer
Hiroshi Kitamura
• 13 Feb 2025
Hiroshi Kitamura, MD, PhD, University of Toyama, Toyama, Japan, comments on the comparison between avemlumab alone and enfortumab vedotin with pembrolizumab in the first-line setting for patients who have received chemotherapy. Avemlumab appears to be effective in patients who have achieved a response to platinum-based chemotherapy, and that maintenance therapy is not typically chosen. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
